Identification of natural inhibitor from Aframomum melegueta targeting survivin and mammalian rapamycin signaling pathway in Kidney Cancer

Abstract

Overactivation of survivin and mammalian rapamycin signaling pathway plays an important role in renal carcinogenesis. Recent studies have shown that extract from Aframomum species produces interesting cytotoxic effects against drug resistance cancer. However, the effect of Aframomum melegueta on renal survivin and mammalian rapamycin signaling pathway have not been studied. In this study, we have described a thorough computational study on the effect of natural compounds from Aframomum melegueta on survivin and mammalian rapamycin target at molecular level. Our results revealed a new class of small molecule inhibitors, namely {1,3}benzodaoxolo{5,6-c} dihydrogingerenone, 5-hydroxy-7-methoxyflavone, apigenin, 3,4-dimethoxyphenylacetone and arctigenin, which effectively inhibit survivin and mammalian rapamycin signaling activity. Furthermore, the ADMET (Adsorption, distribution, metabolism, excretion and toxicological) properties prediction also shows that these compounds had good pharmacological properties with little or no toxicity effect. Collectively, our finding suggests that the natural compounds from Aframomum melegueta reported in this study could serve as a potent therapeutic inhibitor of survivin and mammalian rapamycin in renal cancer cells. Thus, we propose further investigation of these compound to validate our findings.